BRAF and melanoma: NICE recommendations for BRAF testing were released in 2022 and may reduce future variation in clinical practice; however, adherence to guidance should be regularly audited and in this rapidly changing field of melanoma biomarker and therapeutic advancement, national guidance must remain up to date to improve melanoma prognosis and equity of care.2 Although these regional variations are not generalizable to other countries, we expect that these differences may be even greater where there is more restricted healthcare provision.21